The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 46, Issue 9, 2005, Pages 1301-1306

  Spector, Nelson ^a,b   Milito, Cristiane Bedran ^a   Biasoli, Irene ^a   Luiz, Ronir Raggio ^a   Pulcheri, Wolmar ^a   Morais, José Carlos ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Bcl 2; EBV; Hodgkin's lymphoma; International Prognostic Score; p53; Prognosis

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; PROTEIN BCL 2; PROTEIN P53; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; ADVANCED CANCER; ARTICLE; BIOPSY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; RISK ASSESSMENT; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; FEMALE; GENE EXPRESSION; GENES, P53; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 24644441255     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500126034     Document Type: Article

References (25)

1. Diehl V. Chemotherapy or combined modality treatment: the optimal treatment for Hodgkin's disease. J Clin Oncol 2004;22:15-18.
2. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003;225-247.
3. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-3439.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514.
5. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Alvaro T, Bellas C, Castano A, Diez A, Flores T, et al. Hodgkin and Reed - Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689.
6. Vassallo J, Metze K, Traina F, de Souza CA, Lorand-Metze I. The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma 2003;44:483-488.
7. Brink AA, Oudejans JJ, van den Brule AJ Kluin PM, Horstmann A, Ossenkoppele GJ, van Heerde P, Jiwa M, Meijer CJ. Low p53 and high Bcl-2 expression in Reed - Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol 1998;11:376-383.
8. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein - Barr viral genomes in Reed - Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-506.
9. Dantuma NP, Masucci MG. The ubiquitin/proteasome system in Epstein - Barr virus latency and associated malignancies. Semin Cancer Biol 2003;13:69-76.
10. Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G, Vivani S, Bonfante V, Giardini R, Chilosi M, et al. Expression of Epstein - Barr virus latent membrane protein-1 in Hodgkin and Reed - Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res 2003;9:2114-2120.
11. Axdorph U, Porwit-MacDonald A, Sjoberg J, Grimfors G, Eckman M, Wang W, Biberfeld P, Bjorkholm M. Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. Br J Cancer 1999;81:1182-1187.
12. Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR. Hodgkin's disease in the elderly: a population-based study. Br J Haematol 2002;119:432-440.
13. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia-Del-Moral R, Gomez-Marcos F, Menarguez J, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein - Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429-2436.
14. Smolewski P, Robak T, Krykowski E, Blasinska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000;6:1150-1160.
15. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Vivani S, Bonfarte V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, et al. BCL-2 expression in Hodgkin and Reed - Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100:3935-3941.
16. Montalban C, Garcia JF, Abraira V, Gonzalez-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, Garcia-Sanz R, Garcia-Lavana J, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:1664-1673.
17. Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 1994;25:449-454.
18. Murray PG, Billingham LJ, Hassan HT, Flavell JR, Nelson PN, Scott K, Reynolds G, Constandinou CM, Kerr DJ, Devey EC, et al. Effect of Epsteinn - Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999;94:442-447.
19. Mills JL. Data torturing. N Engl J Med 1993;329:1196-1199.
20. Fukuda H, Ohashi Y. A guideline for reporting results of statistical analysis in Japanese Journal of Clinical Oncology. Japan J Clin Oncol 1997;27:121-127.
21. Flavell KJ, Billingham LJ, Biddulph JP, Gray L, Flavell JR, Constandinou CM, Young LS, Murray PG. The effect of Epstein - Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol 2003;14:282-290.
22. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P. Assessment of the prognostic impact of the Epstein - Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. Br J Cancer 2001;84:1227-1234.
23. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418.
24. Auvinen A, Karjalainen S. Possible explanations for social class differences in cancer patient survival. In: Kogevinas M, Pearce N, Susser M, Boffetta P, editors. Social inequalities in cancer. IARC Scientific Publications No. 138. Lyon: International Agency for Research on Cancer; 1997. p 377-397.
25. Spector N, Costa MA, Pulcheri W, Sulgado RC, Nuccci M, Andrade CA, de Morais JC, de Castro O, Scaletsky AF, Brabo E, et al. C-MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil. Cancer 1993;71:2823-2827.